{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T16:53:26Z","timestamp":1770483206031,"version":"3.49.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1016\/j.jinf.2013.09.026","type":"journal-article","created":{"date-parts":[[2013,10,16]],"date-time":"2013-10-16T11:15:31Z","timestamp":1381922131000},"page":"S76-S82","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"S1","title":["Advances towards the prevention of meningococcal B disease: A multidimensional story"],"prefix":"10.1016","volume":"68","author":[{"given":"Marion","family":"Roderick","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Finn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"S2","key":"10.1016\/j.jinf.2013.09.026_bib1","doi-asserted-by":"crossref","first-page":"B51","DOI":"10.1016\/j.vaccine.2009.04.063","article-title":"Global epidemiology of meningococcal disease","volume":"27","author":"Harrison","year":"2009","journal-title":"Vaccine"},{"issue":"S2","key":"10.1016\/j.jinf.2013.09.026_bib2","doi-asserted-by":"crossref","first-page":"B26","DOI":"10.1016\/j.vaccine.2011.12.032","article-title":"The changing and dynamic epidemiology of meningococcal disease","volume":"30","author":"Halperin","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.jinf.2013.09.026_bib3","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S1473-3099(12)70168-8","article-title":"Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data","volume":"12","author":"Novak","year":"2012","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.jinf.2013.09.026_bib4","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1017\/S0950268898001848","article-title":"Is group C meningococcal disease increasing in Europe? A report of surveillance of meningococcal infection in Europe 1993\u20136. European Meningitis Surveillance Group","volume":"122","author":"Connolly","year":"1999","journal-title":"Epidemiol Infect"},{"issue":"10","key":"10.1016\/j.jinf.2013.09.026_bib5","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.3201\/eid1010.040335","article-title":"Disease susceptibility to ST11 complex meningococci bearing serogroup C or W135 polysaccharide capsules, North America","volume":"10","author":"Pollard","year":"2004","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.jinf.2013.09.026_bib6","first-page":"33","article-title":"Development of meningococcal serogroups","volume":"vol. II","author":"Vedros","year":"1987"},{"issue":"28","key":"10.1016\/j.jinf.2013.09.026_bib7","doi-asserted-by":"crossref","first-page":"11557","DOI":"10.1073\/pnas.0704404104","article-title":"Extracellular structure of polysialic acid explored by on cell solution NMR","volume":"104","author":"Azurmendi","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jinf.2013.09.026_bib8","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0140-6736(83)90340-9","article-title":"Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis","volume":"2","author":"Finne","year":"1983","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.jinf.2013.09.026_bib9","doi-asserted-by":"crossref","first-page":"4402","DOI":"10.4049\/jimmunol.138.12.4402","article-title":"An IgG monoclonal antibody to group B meningococci cross-reacts with developmentally regulated polysialic acid units of glycoproteins in neural and extraneural tissues","volume":"138","author":"Finne","year":"1987","journal-title":"J Immunol"},{"issue":"24","key":"10.1016\/j.jinf.2013.09.026_bib10","doi-asserted-by":"crossref","first-page":"21535","DOI":"10.1074\/jbc.M111.221143","article-title":"Structural and functional impairments of polysialic acid by a mutated polysialyltransferase found in schizophrenia","volume":"286","author":"Isomura","year":"2011","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/j.jinf.2013.09.026_bib11","first-page":"195","article-title":"Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba","volume":"14","author":"Sierra","year":"1991","journal-title":"NIPH Ann"},{"issue":"8827","key":"10.1016\/j.jinf.2013.09.026_bib12","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/0140-6736(92)93086-3","article-title":"Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil","volume":"340","author":"de Moraes","year":"1992","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.jinf.2013.09.026_bib13","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/0264-410X(94)00037-N","article-title":"Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Chilean National Committee for Meningococcal Disease","volume":"13","author":"Boslego","year":"1995","journal-title":"Vaccine"},{"issue":"8775","key":"10.1016\/j.jinf.2013.09.026_bib14","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/0140-6736(91)91961-S","article-title":"Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway","volume":"338","author":"Bjune","year":"1991","journal-title":"Lancet"},{"issue":"17\u201318","key":"10.1016\/j.jinf.2013.09.026_bib15","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1016\/j.vaccine.2005.01.063","article-title":"MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain","volume":"23","author":"Oster","year":"2005","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.jinf.2013.09.026_bib16","first-page":"325","article-title":"Vaccinal strategies in response to new epidemiological challenges in 2010. Reasonable hope for a \u201cB\u201d meningococcal vaccine","volume":"70","author":"Nicolas","year":"2010","journal-title":"Med Trop (Mars)"},{"issue":"4","key":"10.1016\/j.jinf.2013.09.026_bib17","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1128\/CVI.13.4.486-491.2006","article-title":"The VR2 epitope on the PorA P1.7-2,4 protein is the major target for the immune response elicited by the strain-specific group B meningococcal vaccine MeNZB","volume":"13","author":"Martin","year":"2006","journal-title":"Clin Vaccine Immunol"},{"issue":"4","key":"10.1016\/j.jinf.2013.09.026_bib18","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1128\/cdli.3.4.444-450.1996","article-title":"Antigenic diversity of meningococcal outer membrane protein PorA has implications for epidemiological analysis and vaccine design","volume":"3","author":"Feavers","year":"1996","journal-title":"Clin Diagn Lab Immunol"},{"issue":"12","key":"10.1016\/j.jinf.2013.09.026_bib19","doi-asserted-by":"crossref","first-page":"5184","DOI":"10.1128\/iai.65.12.5184-5190.1997","article-title":"Human B- and T-cell responses after immunization with a hexavalent PorA meningococcal outer membrane vesicle vaccine","volume":"65","author":"van der Voort","year":"1997","journal-title":"Infect Immun"},{"issue":"6","key":"10.1016\/j.jinf.2013.09.026_bib20","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1084\/jem.20021911","article-title":"Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870","volume":"197","author":"Masignani","year":"2003","journal-title":"J Exp Med"},{"issue":"4","key":"10.1016\/j.jinf.2013.09.026_bib21","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1128\/IAI.72.4.2088-2100.2004","article-title":"Vaccine potential of the Neisseria meningitidis 2086 lipoprotein","volume":"72","author":"Fletcher","year":"2004","journal-title":"Infect Immun"},{"issue":"9","key":"10.1016\/j.jinf.2013.09.026_bib22","doi-asserted-by":"crossref","first-page":"4232","DOI":"10.1128\/IAI.00367-08","article-title":"Fine antigenic specificity and cooperative bactericidal activity of monoclonal antibodies directed at the meningococcal vaccine candidate factor h-binding protein","volume":"76","author":"Beernink","year":"2008","journal-title":"Infect Immun"},{"issue":"1","key":"10.1016\/j.jinf.2013.09.026_bib23","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1128\/IAI.01071-08","article-title":"Factor H-binding protein is important for meningococcal survival in human whole blood and serum and in the presence of the antimicrobial peptide LL-37","volume":"77","author":"Seib","year":"2009","journal-title":"Infect Immun"},{"issue":"9","key":"10.1016\/j.jinf.2013.09.026_bib24","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1099\/mic.0.029876-0","article-title":"The modular architecture of meningococcal factor H-binding protein","volume":"155","author":"Beernink","year":"2009","journal-title":"Microbiology"},{"issue":"8","key":"10.1016\/j.jinf.2013.09.026_bib25","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1473-3099(12)70087-7","article-title":"Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial","volume":"12","author":"Richmond","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jinf.2013.09.026_bib26","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1126\/science.287.5459.1816","article-title":"Whole genome sequencing to identify vaccine candidates against serogroup B meningococcus","volume":"287","author":"Pizza","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.jinf.2013.09.026_bib27","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1086\/656741","article-title":"Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy","volume":"51","author":"Findlow","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"12","key":"10.1016\/j.jinf.2013.09.026_bib28","doi-asserted-by":"crossref","first-page":"6917","DOI":"10.1128\/IAI.68.12.6917-6923.2000","volume":"68","author":"Lapinet","year":"2000","journal-title":"Infect Immun"},{"issue":"17\u201318","key":"10.1016\/j.jinf.2013.09.026_bib29","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/j.vaccine.2005.01.051","article-title":"Meningococcal surrogates of protection\u2014serum bactericidal antibody activity","volume":"23","author":"Borrow","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.jinf.2013.09.026_bib30","series-title":"Requirements for meningococcal polysaccharide vaccine","author":"World Health Organisation","year":"1976"},{"key":"10.1016\/j.jinf.2013.09.026_bib31","doi-asserted-by":"crossref","first-page":"A3","DOI":"10.1136\/adc.2011.212563.6","article-title":"Use of an investigational multicomponent meningococcal serogroup B vaccine (4CMenB) in a clinical trial in 3630 infants","volume":"96","author":"Vesikari","year":"2011","journal-title":"Arch Dis Child"},{"issue":"9816","key":"10.1016\/j.jinf.2013.09.026_bib32","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0140-6736(11)61713-3","article-title":"V72P10 meningococcal B adolescent vaccine study group. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b\/3 randomised, observer-blind, placebo-controlled study","volume":"379","author":"Santolaya","year":"2012","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.jinf.2013.09.026_bib33","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1128\/CVI.00202-12","article-title":"Interlaboratory standardization of the sandwich enzyme-linked immunosorbent assay designed for MATS, a rapid, reproducible method for estimating the strain coverage of investigational vaccines","volume":"19","author":"Plikaytis","year":"2012","journal-title":"Clin Vaccine Immunol"},{"issue":"45","key":"10.1016\/j.jinf.2013.09.026_bib34","doi-asserted-by":"crossref","first-page":"19490","DOI":"10.1073\/pnas.1013758107","article-title":"Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines","volume":"107","author":"Donnelly","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jinf.2013.09.026_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(13)70006-9","article-title":"Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment","author":"Vogel","year":"2013","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"10.1016\/j.jinf.2013.09.026_bib36","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1001\/jama.2012.85","article-title":"European MenB Vaccine Study Group. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial","volume":"307","author":"Gossger","year":"2012","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.jinf.2013.09.026_bib37","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1097\/INF.0b013e3181f59f6d","article-title":"Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial","volume":"29","author":"Snape","year":"2010","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.jinf.2013.09.026_bib38","series-title":"Prophylactic paracetamol in infants decreases fever following concomitant administration of an investigational meningococcal serogroup B vaccine with routine immunizations","author":"Prymula","year":"2011"}],"container-title":["Journal of Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445313002934?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445313002934?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T21:19:07Z","timestamp":1759007947000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163445313002934"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":38,"alternative-id":["S0163445313002934"],"URL":"https:\/\/doi.org\/10.1016\/j.jinf.2013.09.026","relation":{},"ISSN":["0163-4453"],"issn-type":[{"value":"0163-4453","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances towards the prevention of meningococcal B disease: A multidimensional story","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jinf.2013.09.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 The British Infection Association. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}